Cell banks provide the reproducible starting material on which advanced therapies are built. At Minaris, we generate research, master and working cell banks under cGMP conditions, supported by over 20 years of expertise and more than 500 GMP cell banks manufactured.
Our banking services have enabled hundreds of successful submissions to global regulators, including the FDA, EMA and PMDA. Every bank is designed for reliability, traceability and worldwide acceptance.
Sponsors often face challenges such as high attrition rates, long timelines and fragmented service models. Minaris mitigates these issues through:
Every bank undergoes a suite of release tests, which typically include sterility, mycoplasma, STR profiling, karyotyping and viability. For programs with unique requirements, we design custom panels that integrate seamlessly into your regulatory package. Because our analytical scientists and manufacturing teams work closely together, assay development and bank production are closely aligned.
With more than 20 years of banking expertise, 500+ GMP banks manufactured and submissions accepted by global regulators, Minaris offers unmatched experience and infrastructure. Our integrated approach reduces risk, accelerates readiness and provides the consistency needed to scale advanced therapies worldwide.
intro-section does not exist
Minaris Advanced Therapies is dedicated to helping innovators in cell and gene therapy succeed. Whether you are in early-stage development or preparing for commercial launch, our end-to-end expertise, global reach and commitment to quality make us the ideal partner for cell and gene therapy manufacturing and GMP biosafety and analytical testing of all biologics.
